Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG KFO286)
German Federal Ministry of Education and Research (0316190A)
Center for Molecular Medicine Cologne
North Rhine-Westphalia (EFRE-0800397)
Text and Data Mining valid from 2018-07-20
Received: 25 March 2018
Accepted: 21 June 2018
First Online: 20 July 2018
Ethics approval and consent to participate
: Establishment of PDX models from NSCLC patients was approved (EA3/001/06) by the local ethical review committee (Charité Berlin). Written informed consent to participate in the study was obtained from all patients. The research conformed with the principles of the Declaration of Helsinki. The use of clinical data and patient’s material was approved by the institutional review board of the ELK Berlin Chest Hospital. All mice used in the study were handled in accordance with the Guidelines for the Welfare and Use of Animals in Cancer Research [ CitationRef removed ]. Their use was approved by the local responsible authorities (approval no. G 0030/15), according to the German Animal Protection Law.
: Not applicable.
: Hans Lehrach is a chairman of and Felix Dreher is employed at Alacris Theranostics GmbH Berlin, Germany. Jana Rolff, Michael Becker, and Iduna Fichtner are employed by the Experimental Pharmacology and Oncology Berlin-Buch GmbH, Germany. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.